SMS Pharmaceuticals Limited — PPTs, 10-08-2025: Investor Presentation

Here's a summary of the attached investor presentation:

**Financial Highlights:**

SMS Pharmaceuticals reported robust Q1FY26: revenue reached ₹196 Cr (+19% YoY), PAT grew 24% YoY to ₹20.5 Cr, with EBITDA margin steady at 20%. EPS was ₹2.31. FY26 outlook maintains 20% revenue growth and 20% EBITDA margin.

**Strategic Initiatives & Growth Drivers:**

A ₹250 Cr capex plan progresses for expansion, R&D, and CMO growth. Strategies include backward integration for profitability, adding 8-10 new products in 12-18 months, and scaling ibuprofen production to 1,000 MT/month.

**Business Developments:**

Commercial production of key intermediates has started, with a gross margin impact expected in Q2. The company leverages highly accredited manufacturing facilities supporting its diversified product portfolio.

**Market Position & Competitive Advantage:**

SMS Pharma leads in key APIs, notably with Asia's largest Ibuprofen plant. Its strong presence in regulatory markets (88% FY25 revenue) and balanced high-value to high-volume product mix highlight competitive edge.

**Investor Implications:**

Strong Q1 performance and strategic growth initiatives, including capex and new products, signal positive growth potential. Investors should monitor the expected Q2 gross margin impact.